Navigation Links
QRxPharma Announces Strategic Alliance with Liaoning Nuokang Medicines Co Ltd for the Development of Venomics Assets

SYDNEY, Australia and BEDMINSTER, N.J., Sept. 24 /PRNewswire/ -- QRxPharma Limited (ASX: QRX and Pink Sheets: QRXPY), announced today a strategic alliance with Liaoning Nuokang Medicines Co. Ltd. ("Nuokang"), a Chinese biopharmaceutical company based in Shenyang, China, to develop and commercialise QRxPharma's venomics assets for the Chinese market. The strategic alliance involves Nuokang investing US$5.0 million for a controlling interest in a Hong Kong company that holds a license over two of QRxPharma's lead haemostasis product candidates: Textilinin, an antifibrinolytic agent, and Haempatch(TM), a potent pro-coagulant.

The transaction is expected to be completed by mid October 2009. On completion, a minority interest in the Hong Kong company will be held by Venomics Pty Ltd, which is a majority-owned subsidiary of QRxPharma and holds all of the venomics assets of QRxPharma. An affiliated company of Nuokang has also subscribed to a 10% interest in Venomics Pty Limited.

"We are very pleased to announce the strategic alliance of QRxPharma's venomics program with a leading Chinese biopharmaceutical company that has extensive experience in the development, manufacture and sale of therapeutics derived from snake venoms," said Dr. John Holaday, Managing Director and Chief Executive Officer, QRxPharma. "Blood loss in surgery and trauma is a significantly under-served market opportunity, and Nuokang's capabilities and resources will ensure that Textilinin and Haempatch(TM) progress quickly to the clinic."

Dr. Holaday further said that he was particularly pleased to have concluded this deal:

"This strategic alliance provides a great opportunity to extract value for QRxPharma shareholders from the venomics assets without diverting management's attention away from QRxPharma's main prospect with its Dual Opioid(TM) development programme in the area of pain management".

Venomics Pty Limited will be led by Ms. Janette Dixon as CEO and Dr. John Holaday as Chairman of the Board of Directors. Ms. Dixon has extensive experience in the pharmaceutical and biotech sectors and spent a large part of her career working in Asia. Before joining QRxPharma in 2008, Ms. Dixon was the Managing Director of Pacific Pharmaceuticals Ltd, one of New Zealand's largest pharmaceutical manufacturing companies. "The Hong Kong entity holds the license to commercialise Textilinin and Haempatch(TM) in China. Data generated through the development of these products in China will support partnering activities in other territories. The Nuokang partnership minimizes the development costs for Textilinin and Haempatch(TM) while maximizing future potential returns to QRxPharma," said Ms. Dixon.

Nuokang is a leading, fully integrated China-based biopharmaceutical company focused on haematological and cardiovascular products. Nuokang's flagship product, Baquting, is one of China's most widely used haemocoagulase products for the treatment or prevention of bleeding. Baquting contains an enzyme obtained from the venom of the snake species Bothrops atrox.

Textilinin is a novel recombinant peptide that inhibits plasmin, a key enzyme in the fibrinolytic pathway and has potential to reduce blood loss in major surgery. In pre-clinical testing, Textilinin has compared favourably to other antifibrinolytic products such as Trasylol(R) (aprotinin), a product used to reduce perioperative blood loss in patients undergoing coronary artery bypass graft surgery (CABG). Trasylol(R) enjoyed peak annual sales in excess of US$300 million before it was withdrawn from many markets due to concerns over its side effect profile.

Haempatch(TM) is a novel prothrombin activating protease, with properties similar to the human Factor Xa clotting factor. It is highly effective in clotting blood and stopping blood flow (haemostasis) and has compared favourably to thrombin in pre-clinical testing. Both Haempatch(TM) and the native form of Textilinin were originally isolated from the venom of the Australian Common Brown snake (Pseudonaja textilis) by researchers at The University of Queensland (UQ). A collaborative R&D project has been ongoing since 2003 between QRxPharma and this UQ research team to further develop Textilinin and Haempatch(TM) and screen Australian snake venoms for therapeutic leads. A jointly owned pipeline of early stage candidates has been developed.

Forward Looking Statements

This press release contains forward-looking statements that involve risks and uncertainties. The forward-looking statements contained herein represent the judgment of QRxPharma as of the date of this release. These forward-looking statements are not guarantees for future performance. Actual results could differ materially from those currently anticipated to due to a number of factors including risks relating to the stage of products under development; uncertainties relating to clinical trials; dependence on third parties; future capital needs; and risks relating to the commercialization of the Company's proposed products.

About QRxPharma

QRxPharma (ASX: QRX and Pink Sheets: QRXPY) is a clinical-stage specialty pharmaceutical company focused on the development and commercialisation of new treatments for pain management and central nervous system (CNS) disorders. Based on a development strategy which focuses on enhancing and expanding the clinical utility of currently marketed compounds, the Company's product portfolio includes both late and early stage clinical drug candidates with the potential for reduced risk, abbreviated development paths, and improved patient outcomes. The Company intends to directly commercialise its products in the US and seek strategic partnerships abroad. QRxPharma's lead compound, MoxDuo(TM) IR, the first combination opioid product for the improved control of moderate to severe pain, successfully completed a Phase 3 study and a pilot Combination Rule study and met primary and secondary endpoints. The Company's preclinical and clinical pipeline includes other technologies in the fields of pain management, neurodegenerative disease and venomics. For more information:

SOURCE QRxPharma Limited
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. QRxPharma Expands Management Team with the Addition of Dr. Jesus Soriano as Executive Vice President
2. QRxPharma Begins Trading on the International OTCQX
3. QRxPharma Initiates Second Phase III Clinical Trial for its Dual Opioid Pain Therapy
4. I-Therapeutix, Inc. Announces Company Name Change
5. President Clinton Hosts Special Session on Northern Ireland; Announces New Commitments Focused on Harnessing Innovation for Development
6. Caraco Pharmaceutical Laboratories, Ltd. Announces Resignation of Georges Ugeux from Board of Directors
7. US Farms, Inc. Announces Broker Network Agreement With Sunshine Specialties for Aloe365 Products
8. ReBuilder Medical Technologies, Inc. Announces Medicare Billing Ability for its ReBuilder Product
9. Cardiogenesis Announces Successful Symposium at the Transcatheter Cardiovascular Therapeutics (TCT) Meeting
10. Strategic Information Group Announces QAD Enterprise Validation Partnership
11. Natural Alternatives International, Inc. Announces Fiscal 2009 Q4 and Full Year Results
Post Your Comments:
(Date:11/26/2015)... ... November 26, 2015 , ... ... retro-fused, self-animating trailer titles with ProTrailer: Vintage. This newly styled ProTrailer pack comes ... titles work with any font, giving users limitless opportunities to stylize and create ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... for all, Water For Empowerment ™ attracts volunteers together who want to ... by empowering women as key stakeholders in the process. The non-profit launched its ...
(Date:11/25/2015)... ... 25, 2015 , ... TyloHelo Inc , North America’s ... Sauna accessories help improve the bather experience in the sauna, and the accessories ... the purist looking for simplicity in design to accessories that encourage a greater ...
(Date:11/25/2015)... ... November 25, 2015 , ... For the first time, Vitalalert ... Organizations, One Beat ” campaign. The partnership between the two groups began in 2014 ... MAP International’s cause. , MAP International was founded in 1954 and is an international ...
(Date:11/25/2015)... ... ... On November 25, 2015, officials of Narconon Arrowhead , the drug ... a new cutting edge recovery program that has been 50 years in the making. ... individuals with the purpose to free addicts from the symptoms and negative behaviors of ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... Nederland, November 26, 2015 ... Een nieuwe aanpak combineert immunotherapie met Bremachlorin-photodynamische ... ) --> ...      (Photo: ) ... Universitair Medisch Centrum (LUMC) blijkt ...
(Date:11/26/2015)... Research and Markets ( ) ... Future Horizons and Growth Strategies in the Japanese ... Segment Forecasts, Competitive Intelligence, Emerging Opportunities" report ... --> This new 247-page report ... drug monitoring market, including emerging tests, technologies, instrumentation, ...
(Date:11/26/2015)... 2015 --> ... potential att använda SyMRI för att hitta ... patienter med multipel skleros (MS) eller hjärntumörmetastaser ... AB för att kunna använda SyMRI Research ... SyMRI kan man generera flera konstrastbilder från ...
Breaking Medicine Technology: